Abstract:BACKGROUND AND OBJECTIVE:Cisplatin-resistance in lung cancer cells is general in clinic, hence it is significant to investigate the mechanisms of cisplatin-resistant and develop new methods of reversing drug-resistance. Recent researches showed that miRNA could regulate cell growth, apoptosis, migration and invasion even in drug therapy in cancer by its target gene. The aim of this study is to investigate the effects and molecular mechanisms of miR-503 on reversing the cisplatin-resistance in lung cancer DDP-resistant cell line A549/DDP.METHODS:MTS assay was employed to determine the effect of miR-503 on A549/DDP' sensitivity to cisplatin. Apoptosis rate and intracellular concentration of rhodamine-123 (Rh-123) were determined by flow cytometry, the expression of multi-drugs resistant proteins MDR1 and MRP1, ERCC1, RhoE, Survivin and Bcl-2 were determined by Western blot and real time PCR. The phosphorylation of Akt was analyzed by Western blot, the transcriptional activities of NF-κB and AP-1 were detected by dual-luciferase reporter gene systems.RESULTS:MiR-503 was able to increase the cisplatin sensitivity of A549/DDP. After treatment with miR-503, the reverse folds (RF) to cisplatin was 2.48 fold, the intracellular level of Rh-123 was 2.49 fold, the apoptosis rate was 10.3 fold, the expressions of several drug-resistant related proteins, such as MDR1, MRP1, ERCC1, Survivin and Bcl-2 were downregulated significantly, as shown by WB, in contrast, the level of RhoE was elevated, the mRNA epression of MDR1 was 18.5%, the mRNA epression of MRP1 was 22.3%, the mRNA epression of ERCC1 was 18.6%, the mRNA epression of Survivin was 42.8%, the mRNA expression of Bcl-2 was 68.1%, the mRNA epression of RhoE was 206.5%, in addition, the phosphorylation of Akt decreased and transcriptional activities of NF-κB was 53.7%, AP-1 was 47.4% compared with control group.CONCLUSIONS:MiR-503 was able to reverse the cisplatin resistance of A549/DDP. MiR-503 processed this kind of effect by inhibiting the drug efflux, downregulating the expression of drug-resistant related proteins and promoting cell apoptosis.

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.

MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer

Downregulation of Microrna-196A Enhances the Sensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin Treatment

MiR-199a-3p Enhances Cisplatin Sensitivity of Cholangiocarcinoma Cells by Inhibiting Mtor Signaling Pathway and Expression of MDR1

Upregulation of Microrna-181A-5p Increases the Sensitivity of HS578T Breast Cancer Cells to Cisplatin by Inducing Vitamin D Receptor-Mediated Cell Autophagy

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

Mir-488 Inhibits Proliferation And Cisplatin Sensibility In Non-Smallcell Lung Cancer (Nsclc) Cells By Activating The Eif3a-Mediated Ner Signaling Pathway

Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin

The Role of miRNAs in Cisplatin-Resistant HeLa Cells.

Microrna-302a Sensitizes Testicular Embryonal Carcinoma Cells to Cisplatin-Induced Cell Death

Resveratrol Enhances Inhibition Effects of Cisplatin on Cell Migration and Invasion and Tumor Growth in Breast Cancer MDA-MB-231 Cell Models In Vivo and In Vitro

MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma

MicroRNA-218 Regulates the Chemo-Sensitivity of Cervical Cancer Cells Through Targeting Survivin.

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer

TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis

Blocking of SIRT7/FOXO3a Axis by miR-152-3p Enhances Cisplatin Sensitivity in Breast Cancer

MicroRNA-218 Promotes Cisplatin Resistance in Oral Cancer Via the PPP2R5A/Wnt Signaling Pathway

MicroRNA-218 Regulates Cisplatin (DPP) Chemosensitivity in Non-Small Cell Lung Cancer by Targeting RUNX2

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.

The Reversing and Molecular Mechanisms of Mir-503 on the Drug-resistance to Cisplatin in A549/DDP Cells

Upregulation of Microrna-451 Increases Cisplatin Sensitivity of Non-Small Cell Lung Cancer Cell Line (A549)